公开(公告)号：US20210079015A1

公开(公告)日：2021-03-18

申请号：US16764525

申请日：2018-11-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Mika LINDVALL ,  James R. MANNING ,  Glenn MCENROE

IPC: C07D498/04

Abstract: The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20200276169A1

公开(公告)日：2020-09-03

申请号：US16823485

申请日：2020-03-19

Applicant: Novartis AG

Inventor： Virender Singh AULAKH ,  Anthony CASAREZ ,  Xiaodong LIN ,  Mika LINDVALL ,  Glenn MCENROE ,  Heinz Ernst MOSER ,  Folkert RECK ,  Meiliana TJANDRA ,  Robert Lowell SIMMONS ,  Aregahegn YIFRU ,  Qingming ZHU

IPC: A61K31/427 ,  A61K45/06 ,  C07D487/04 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  C07D417/14

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

公开(公告)号：US20180273522A1

公开(公告)日：2018-09-27

申请号：US15762724

申请日：2016-09-20

Applicant: Novartis AG

Inventor： Eric AUBIN ,  Anthony CASAREZ ,  Andreas FISCH ,  Zaixing LI ,  Mika LINDVALL ,  Heinz Ernst MOSER ,  Michael MUTZ ,  Folkert RECK ,  Bernd Ulrich RIEBESEHL ,  Marc SCHOENHENTZ ,  Vijay SETHURAMAN ,  Robert Lowell SIMMONS

IPC: C07D417/14 ,  A61P31/04

CPC classification number: C07D417/14 ,  A61P31/04 ,  C07B2200/13

Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

公开(公告)号：US20190247392A1

公开(公告)日：2019-08-15

申请号：US16210968

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Jeffrey T. BAGDANOFF ,  Yu DING ,  Wooseok HAN ,  Zilin HUANG ,  Qun JIANG ,  Xianming JIN ,  Xiang KOU ,  Patrick LEE ,  Mika LINDVALL ,  Zhongcheng MIN ,  Yue PAN ,  Sabina PECCHI ,  Keith Bruce PFISTER ,  Daniel POON ,  Vivek RAUNIYAR ,  Xiaojing Michael WANG ,  Qiong ZHANG ,  Jianguang ZHOU ,  Shejin ZHU

IPC: A61K31/497 ,  A61K31/5355 ,  A61K31/4436 ,  A61K31/4433 ,  A61K31/44 ,  C07D403/06 ,  C07D401/12 ,  C07D401/06 ,  C07D213/73 ,  C07D413/14 ,  C07D241/20 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D498/04 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

公开(公告)号：US20190231752A1

公开(公告)日：2019-08-01

申请号：US16380243

申请日：2019-04-10

Applicant: Novartis AG

Inventor： Virender Singh AULAKH ,  Anthony CASAREZ ,  Xiaodong LIN ,  Mika LINDVALL ,  Glenn MCENROE ,  Heinz Ernst MOSER ,  Folkert RECK ,  Meiliana TJANDRA ,  Robert Lowell SIMMONS ,  Aregahegn YIFRU ,  Qingming ZHU

IPC: A61K31/427 ,  A61K31/433 ,  C07D487/04 ,  A61K31/4545 ,  A61K31/496 ,  C07D417/14 ,  A61K31/4439 ,  A61K31/454 ,  A61K45/06

CPC classification number: A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K45/06 ,  C07D417/14 ,  C07D487/04 ,  Y02A50/473 ,  Y02A50/481

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

公开(公告)号：US20180028532A1

公开(公告)日：2018-02-01

申请号：US15672568

申请日：2017-08-09

Applicant: Novartis AG

Inventor： Jeffrey T. BAGDANOFF ,  Yu DING ,  Wooseok HAN ,  Zilin HUANG ,  Qun JIANG ,  Xianming JIN ,  Xiang KOU ,  Patrick LEE ,  Mika LINDVALL ,  Zhongcheng MIN ,  Yue PAN ,  Sabina PECCHI ,  Keith Bruce PFISTER ,  Daniel POON ,  Vivek RAUNIYAR ,  Xiaojing Michael WANG ,  Qiong ZHANG ,  Jianguang ZHOU ,  Shejin ZHU

IPC: A61K31/497 ,  A61K31/4433 ,  A61K31/5355 ,  A61K31/44 ,  A61K31/4436

CPC classification number: A61K31/497 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  A61K2121/00 ,  C07D213/73 ,  C07D241/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/14 ,  C07D498/04

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.